Anti-TNF-Alpha Therapy and Systemic Vasculitis

• Main Authors: Pierre-André Jarrot, Gilles Kaplanski
• Format: Article
• Language: English
• Published: Hindawi Limited 2014-01-01
• Series: Mediators of Inflammation
• Online Access: http://dx.doi.org/10.1155/2014/493593

TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet’s disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis.